Clinical trials
Progression clinical trials
Below are recruiting progression clinical trials, each written for real people, not researchers. We’re tracking 711 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05425004RecruitingPhase 2
Cabozantinib for recurrent or worsening meningioma tumors
This Phase 2 trial studies cabozantinib, a targeted pill medicine, for meningioma that has come back or is getting worse after standard treatment like surgery or radiation. It aims to shrink tumors and slow progression when other options may have limited benefit.
Miami, FloridaAges 18 years+ - NCT05382572Recruiting
Pulmonary fibrosis community registry for patients and families
This study builds a community registry to learn about people affected by pulmonary fibrosis and related lung conditions, including patients, caregivers, and close family. By joining, you help researchers better understand needs and experiences in the real world.
Chicago, IllinoisAges 18 years+ - NCT05361694Recruiting
Study aims to distinguish stable vs worsening early myeloma
This study looks at two different “precursor” conditions that can happen before multiple myeloma: MGUS and smoldering myeloma (SMM). Researchers want to better tell which cases are more likely to progress, using blood/urine tests and sometimes bone marrow tissue.
Miami, FloridaAges 18 years+ - NCT05356104RecruitingPhase 2
GLP-1 treatment to slow small blood-vessel brain damage
This Phase 2 study tests whether a GLP-1–like medicine can slow worsening “small vessel” disease changes in the brain and related walking and thinking problems. It aims to see if the treatment can prevent progression in people who already show early brain changes on MRI.
Wenzhou, ZhejiangAges 55–80 - NCT05318196Recruiting
Predict kidney disease risk and progression from patient data
This trial looks at ways to predict how kidney disease may develop, change, or cause complications using information from patients. It may help doctors identify people at higher risk and tailor care earlier.
ToulouseAges 18–99 - NCT05320822Recruiting
Rehab program study for recent mild concussion
This study tests a practical rehabilitation approach for people with a recent mild concussion (mTBI). You may be able to join if your injury happened recently and your symptoms match a “mild” concussion pattern on your medical record.
Fort Liberty, North CarolinaAges 18–99 - NCT05301881RecruitingPhase 2
Continuing current treatment after local treatment for limited cancer growth
This trial tests whether continuing your current therapy after getting local treatment (like surgery or radiation) for a small area of cancer growth is safe and effective. It may help you keep the same treatment longer before switching to a new one.
AlkmaarAges 18 years+ - NCT05278208RecruitingPhase 1/Phase 2
Lutathera for high-grade brain tumors that returned or got worse
This trial tests if Lutathera, a radioactive drug that targets certain tumors, can help children and young adults with high-grade brain tumors or meningiomas that have come back or are growing. It aims to see if the treatment is safe and works.
Aurora, ColoradoAges 4–39 - NCT05283226RecruitingPhase 2
Oral anti-cancer pill plus paclitaxel after immunotherapy failure
This Phase 2 trial studies an oral study drug (NRC-2694-A) given with paclitaxel to treat head and neck squamous cell cancer that has come back or spread after immunotherapy. It tests whether this combination is safer and works better than expected for people whose cancer progressed on immune checkpoint inhibitors.
Fullerton, CaliforniaAges 18 years+ - NCT05204017Recruiting
Study platform to better understand and treat ALS
This study uses a comprehensive analysis platform to better understand ALS (and related conditions) and help find ways to “remedy and eliminate” it. If you have ALS or are a healthy control who can safely complete questionnaires and possibly an MRI, you may be able to contribute data that researchers use to improve care.
Edmonton, AlbertaAges 18 years+ - NCT05177809Recruiting
Study of RFC1 gene changes in patients and healthy controls
This study tracks people with a specific genetic cause of RFC1-related disease, and compares them with healthy people without nervous system or mental health conditions. It helps researchers learn how the condition develops over time and what changes to watch for.
Melbourne, VictoriaAges 18 years+ - NCT05104983RecruitingPhase 2
Sirolimus to prevent first seizures in babies with TSC
This Phase 2 study tests whether sirolimus (a targeted medicine) can stop or slow the start of seizures in very young babies diagnosed with tuberous sclerosis complex (TSC). If seizures are prevented early, it may also help protect early brain development.
Birmingham, AlabamaAges 1 day–6 months - NCT05121012Recruiting
PET brain scan study for synaptic loss in MSA or PSP
This study uses brain scans (PET, and possibly spinal fluid) to measure changes linked to “synaptic loss” in people with multiple system atrophy (MSA) or progressive supranuclear palsy (PSP). It may help researchers understand disease changes and how they relate to symptoms, which could guide future treatments.
ExeterAges 45–80 - NCT05100992Recruiting
Bifurcation heart procedure registry for adults
This study is a real-world registry that follows adults who are getting a specific type of heart stent procedure in a forked artery. It helps doctors learn what happens before and after the procedure and improve care.
Minneapolis, MinnesotaAges 18 years+ - NCT05100940Recruiting
Study after a heart procedure complication
This trial looks at what happens after complications during or after a heart procedure called coronary angiography or PCI. It may help improve care and outcomes for people who experience a problem during treatment.
Minneapolis, MinnesotaAges 18 years+ - NCT05023018RecruitingPhase 2
NEO100 for recurrent or progressive high-grade meningioma
This trial studies NEO100, a treatment for adults and children (age 12+) with Grade II or III meningioma that has come back or kept growing after surgery and radiation. It may help shrink tumors or slow growth when standard options have not worked well enough.
Los Angeles, CaliforniaAges 12 years+ - NCT05024175Recruiting
Follow-up for people who received CAR T-cell therapy
This study is for people who previously received CAR T cells at the Dana-Farber/Harvard Cancer Center (DF/HCC). It mainly checks how you’re doing over the long term after treatment, and asks you to take part in follow-up visits or procedures.
Boston, MassachusettsAges 18 years+ - NCT05065060Recruiting
Parkinson study tracking health online and long-term
This study aims to better understand Parkinson’s disease over time by collecting health information online. You may join if you have Parkinson’s, or if you don’t, to compare changes and help researchers find useful markers.
San Francisco, CaliforniaAges 18 years+ - NCT05033990Recruiting
Study of early COPD changes using breathing tests and scans
This study follows people with early COPD patterns (or no lung disease) to understand how COPD starts and progresses over time. You may have breathing tests and possibly CT scans, and some participants may join an added lung procedure (bronchoscopy).
Birmingham, AlabamaAges 30–55 - NCT04989725RecruitingPhase 2
Precision radiation for a few new cancer spots while on treatment
This trial tests a precise, high-dose radiation technique (SABR) for people whose cancer has started to grow again in only a few spots despite ongoing medication. The goal is to control those new growths while continuing your current treatment.
Montreal, QuebecAges 18 years+ - NCT04966481RecruitingPhase 3
Palbociclib plus cetuximab versus cetuximab alone
This trial studies whether adding palbociclib to cetuximab works better than cetuximab by itself for head and neck cancer that is growing again after an anti–PD-1/PD-L1 treatment. It is for people whose tumor has a specific gene change (CDKN2A loss) and who have not had too many prior treatments.
Worthington, MinnesotaAges 18 years+ - NCT04946370RecruitingPhase 1/Phase 2
Pembrolizumab plus prostate cancer drug, with or without radiation
This early-phase trial tests pembrolizumab (an immune therapy) plus an androgen-receptor–blocking prostate cancer drug, and possibly a targeted radiation treatment. It’s for men with prostate cancer that has spread and keeps worsening despite standard hormone therapy, aiming to shrink tumors and improve control of the disease.
Boston, MassachusettsAges 18 years+ - NCT04905693Enrolling by invitationPhase 3
Extension inhaled treprostinil study for fibrotic lung disease
This is an add-on (extension) study testing whether continuing inhaled treprostinil can help people with fibrotic lung disease who took part in earlier related studies. It mainly continues treatment and follow-up for eligible participants.
Birmingham, AlabamaAges 40 years+ - NCT04923126RecruitingPhase 1/Phase 2
Mirdametinib for children with low-grade brain tumors
This Phase 1/2 study tests mirdametinib, a targeted medicine, in children and young adults with low-grade glioma (a slower-growing brain tumor). It aims to find the best dose and see how well the treatment works, especially for tumors with certain “MAPK pathway” changes.
Memphis, TennesseeAges 2–24
Hear when a new Progression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for progression?
- Yes. Clin2 currently lists 711 recruiting progression studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a progression trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a progression trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.